Collaboration Opportunities in Hurler Syndrome (MPS I-H)

Collaboration opportunities in Hurler syndrome (MPS I-H) research

Progress in severe MPS I (Hurler syndrome) relies on strong collaboration between academic researchers, clinical teams, patient organisations and industry partners. This page highlights practical routes for collaboration across discovery science, translational research, clinical studies, registries and education.

Use this resource to identify partnership opportunities, align your work with existing initiatives and connect with others advancing MPS I-H research globally.

For researchers, research-focused clinicians and collaborators. This content is not an invitation to invest or a call for patient participation. All collaborations remain subject to institutional, ethical and regulatory approval.
Illustration concept: interconnected researchers, clinicians and families surrounding DNA and brain icons

The case for collaborative research

Hurler syndrome is ultra-rare, biologically complex and demanding to study. Individual centres cannot address all research questions independently. Collaborative research enables:

  • Access to sufficient participant numbers for robust preclinical and clinical analysis
  • Pooling of specialist expertise across biology, gene therapy, HSCT, ERT, imaging and neurocognition
  • Development of shared protocols, outcome measures and registry standards
  • More rapid translation of laboratory findings into early-phase studies

Research priorities · Biomarkers & outcomes

Basic and translational science partnerships

Preclinical research in MPS I-H benefits significantly from shared resources, aligned methods and cross-laboratory validation.

  • Coordinated use and harmonisation of validated animal models and endpoints
  • Joint development of gene delivery platforms and CNS-targeting strategies
  • Shared in vitro and ex vivo systems for vector testing and safety assessment
  • Standardised assays for GAG measurement, imaging and composite outcomes

Preclinical tools & models · Vector design & mechanism · Efficacy outcomes

Shared cohorts, follow-up and outcomes research

Clinical collaboration addresses the challenges posed by small patient populations and long-term disease trajectories.

  • Cross-centre analyses of outcomes following HSCT and ERT
  • Joint studies of cardiac, skeletal, respiratory and neurocognitive progression
  • Harmonised registry datasets with agreed core variables and timelines
  • Multi-country health services and quality-of-life research

Follow-up & registries · Long-term outcomes · Living with Hurler syndrome

Statistics, modelling and health economics

  • Bayesian and adaptive trial designs for small populations
  • Integration of biomarkers and multi-domain outcomes
  • Real-world evidence and cost-effectiveness modelling
  • PK/PD translation and trial simulation approaches

Training and capacity building

  • Joint PhD, MD/PhD and fellowship programmes
  • Shared teaching materials and case-based learning
  • Cross-institution mentorship and exchange schemes
  • Webinars and collaborative teaching initiatives

How to propose collaboration

Clear, focused proposals help collaboration discussions progress efficiently. When contacting the team, please include:

  • Your institution, role and specialist expertise
  • The MPS I-H research area you are working in
  • A brief outline of your project and current stage
  • The type of collaboration you are seeking

Use the main contact route on hurlersyndrome.org (once available) and clearly indicate that your enquiry relates to research collaboration.

Contact us

Collaboration opportunities at a glance

For researchers overview

Audience, themes and core research resources.

Research priorities

Key questions across CNS, skeletal, cardiac and gene therapy.

Preclinical tools & models

Animal models, assays and laboratory systems.

Biomarkers & outcomes

Connecting molecular correction to clinical benefit.

Follow-up & registries

Long-term data and real-world evidence.

Clinical trials roadmap

From preclinical data to first-in-human studies.

Scroll to Top